Beneath the surface: Novel insights into Amivantamab-induced acneiform rash
- PMID: 38971041
- DOI: 10.1016/j.ejca.2024.114198
Beneath the surface: Novel insights into Amivantamab-induced acneiform rash
Keywords: Acneiform rash; Amivantamab; Skin toxicity; Ulcerative scalp lesions.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.Clin Exp Dermatol. 2004 Mar;29(2):138-40. doi: 10.1111/j.1365-2230.2004.01466.x. Clin Exp Dermatol. 2004. PMID: 14987267
-
Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.Eur J Dermatol. 2007 Nov-Dec;17(6):552-3. doi: 10.1684/ejd.2007.0286. Epub 2007 Oct 19. Eur J Dermatol. 2007. PMID: 17951151 No abstract available.
-
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.Pharmacotherapy. 2013 Oct;33(10):1126-9. doi: 10.1002/phar.1308. Epub 2013 Jun 6. Pharmacotherapy. 2013. PMID: 23744830 Clinical Trial.
-
Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.J Cosmet Dermatol. 2023 Aug;22(8):2150-2157. doi: 10.1111/jocd.15704. Epub 2023 Mar 16. J Cosmet Dermatol. 2023. PMID: 36924348 Review.
-
Management of Dermatologic Complications of Lung Cancer Therapies.Curr Treat Options Oncol. 2015 Oct;16(10):50. doi: 10.1007/s11864-015-0368-y. Curr Treat Options Oncol. 2015. PMID: 26338208 Review.
Cited by
-
Erosive Pustular Dermatosis and Amivantamab for Lung Cancer: A Case Report.Case Rep Dermatol. 2025 Jun 13;17(1):263-267. doi: 10.1159/000546616. eCollection 2025 Jan-Dec. Case Rep Dermatol. 2025. PMID: 40635880 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources